In this study, Keytrudademonstrated a five-year overall survival rate of 23.2% in treatment-naïve patients (n=101) and 15.5% in previously treated patients (n=449).
Of note, the five-year OS rate among patients whose tumors expressed PD-L1 (tumor proportion score [TPS] ≥50%) was 29.6% in treatment-naïve patients and 25.0% in previously treated patients (n=138).
These findings, which represent the longest follow-up for Keytrudain lung cancer, were highlighted at the 2019 American Society of Clinical Oncology (ASCO) annual meeting (Abstract #LBA9015) during the official press programme and presented during a poster discussion on Sunday, June 2.
After 60.6 months (range, 51.8 to 77.9) of median follow-up, results from KEYNOTE-001 demonstrated the effect of Keytrudamonotherapy across primary and secondary endpoints, including OS, objective response rate and duration of response.
The investigator-reported ORR was 41.6% (95% CI, 31.9-51.8) in treatment-naïve patients and 22.9% (95% CI, 19.1-27.1) in previously treated patients. Median DOR was 16.8 months (range, 2.1+ to 55.7+) and 38.9 months (range, 1.0+ to 71.8+), respectively.
Among the 60 patients who received two or more years of treatment with KEYTRUDA, the five-year OS rate was 78.6% in treatment-naïve patients and 75.8% in previously treated patients. The ORR in these patients was 86% and 91%, respectively.
Median DOR was 52.0 months (range, 10.2 to 55.7+) in treatment-naïve patients and was not reached (range, 12.5 to 71.8+) in previously treated patients.
The safety profile of Keytrudawas consistent with what has been seen in previously reported studies among patients with advanced NSCLC.
Treatment-related adverse events (TRAEs) of any grade occurred in 71% (n=388) of patients receiving Keytruda; grade 3-5 TRAEs occurred in 13% of patients. Immune-mediated adverse events were reported in 17% of patients.
Hypothyroidism was the most commonly reported immune-mediated adverse event, followed by pneumonitis, hyperthyroidism and skin toxicities.
New and updated data from the Phase 3 KEYNOTE-189 trial evaluating Keytrudain combination with ALIMTA (pemetrexed) and platinum (cisplatin or carboplatin) for the first-line treatment of metastatic nonsquamous NSCLC compared with pemetrexed plus platinum alone, will also be presented on Sunday, June 2 at ASCO (Abstract #9013).
An updated analysis of the OS endpoint showed that after a median follow-up of 18.7 months (range, 0.2 to 30.9), Keytrudain combination with pemetrexed-platinum chemotherapy reduced the risk of death by 44% compared with chemotherapy alone (HR=0.56 [95% CI, 0.45-0.70]; median OS 22.0 months vs. 10.7 months).
An improvement in progression-free survival was also observed, with a 52% reduction in the risk of progression or death compared with chemotherapy alone (HR=0.48 [95% CI, 0.40-0.58]; median PFS 9.0 months vs. 4.9 months).
Fifty four percent of patients in the chemotherapy alone arm received subsequent immunotherapy, including 41% who received in-study crossover.
New findings at ASCO from KEYNOTE-189 also include the first-time presentation of the progression-free survival 2 study endpoint, a clinical endpoint used to assess the impact of next-line treatment on disease control, in the entire study population and different PD-L1 subgroups.
Among patients who received Keytrudain combination with chemotherapy, findings showed a 51% reduction in risk from time of randomisation to objective tumor progression on next-line treatment or death from any cause, whichever comes first, compared with patients who received chemotherapy alone (HR=0.49 [95% CI, 0.40-0.59]; median PFS2 17.0 months vs. 9.0 months).
Results were consistent across all three PD-L1 categories evaluated with a 54% reduction in patients with a TPS
AstraZeneca launches Phase III THARROS trial for BREZTRI in COPD to assess cardiopulmonary outcomes
Merck finalises acquisition of Harpoon Therapeutics Inc
Pfizer reveals strong efficacy data for ABRYSVO in older adults against RSV
Nuvalent's NVL-520 receives FDA breakthrough therapy designation
Dassault Systèmes enhances patient care with virtual twin experience at Paris hospital
Pulmonx initiates CONVERT II trial for AeriSeal System in COPD treatment
Priority Review of Dupixent underway by FDA for COPD treatment
AstraZeneca boosts vaccine portfolio with acquisition of Icosavax
AstraZeneca reports positive resultsfor Tagrisso in Stage III lung cancer trial
AstraZeneca announces US acceptance of BLA for datopotamab deruxtecan to treat lung cancer
Erasca agrees clinical trial deal with Novartis to study naporafenib in combination with trametinib
FDA accepts Bristol Myers Squibb's Augtyro application for Priority Review